{"id":"NCT00438360","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis","officialTitle":"A 24-week, Double-blind, Randomized, Placebo-controlled, Multicenter Study, to Evaluate the Effectiveness of Cyclosporine 2,5 mg/kg/Day Bid Twice a Week on Reducing Relapse Rate, in Maintenance Patients With Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2007-02-22","resultsPosted":"2011-08-09","lastUpdate":"2011-08-09"},"enrollment":243,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Cyclosporine A microemulsion","otherNames":["Neoral"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cyclosporine A","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.","primaryOutcome":{"measure":"Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score","timeFrame":"24 weeks","effectByArm":[{"arm":"Cyclosporine A","deltaMin":87,"sd":null},{"arm":"Placebo","deltaMin":36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":160},"commonTop":["Abdominal pain upper","Hypertriglyceridaemia"]}}